$0.765
+0.075 (+9.76%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
BRNS 相似圖表分析預測
Alphio's BRNS stock price prediction model matches the current Barinthus Biotherapeutics PLC tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.77 (+0.89%). The 1-week path is $0.76 (-0.52%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Barinthus Biotherapeutics PLC 股票嗎?
Barinthus Biotherapeutics PLC is currently not a strong buy due to high RSI at 85.243, indicating overbought conditions, and significant recent losses with a 1-year change of -36.38%.
BRNS 股價於 Tuesday 收在 $0.77,此前上漲 +9.76%
Barinthus Biotherapeutics PLC (BRNS) last closed at $0.765, gaining +9.76%. These facts feed the 1-day and 1-week BRNS price prediction above.
預測驅動因素
Barinthus Biotherapeutics PLC(BRNS)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bullish
相似圖表形態
近期走勢與 BRNS 最接近的股票,依相似度排序。
BRNS 季節性分析
Historically the probability of a positive September return for BRNS is 11.90%. October offers the highest probability of a positive month at 50.00%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
BRNS 十年價格預測
| 月份 | 最低價 | 平均價 | 最高價 | 潛在報酬率 |
|---|---|---|---|---|
| Sep 2026 | $1.30 | $1.55 | $1.80 | +102.55% |
| Oct 2026 | $1.44 | $1.66 | $1.84 | +116.87% |
| Nov 2026 | $1.25 | $1.39 | $1.66 | +81.88% |
| Dec 2026 | $1.59 | $1.81 | $2.00 | +136.39% |
2026 年,Barinthus Biotherapeutics PLC(BRNS)預計區間為 $1.25 至 $2.00。
Barinthus Biotherapeutics PLC 2026 年月度預測
2026 年 Sep,Barinthus Biotherapeutics PLC 預計均價 $1.55,最低 $1.30,最高 $1.80。
2026 年 Oct,Barinthus Biotherapeutics PLC 預計均價 $1.66,最低 $1.44,最高 $1.84。
2026 年 Nov,Barinthus Biotherapeutics PLC 預計均價 $1.39,最低 $1.25,最高 $1.66。
2026 年 Dec,Barinthus Biotherapeutics PLC 預計均價 $1.81,最低 $1.59,最高 $2.00。
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。